Treatment of acute leukemia in children: Recent advances and future challenges

Expert Review of Anticancer Therapy

Volumn 1, Issue 3, 2001, Pages 479-486

  Marco, Fernando ^a   Bureo, Encarna ^a   Bermúdez, Arancha ^a   Fernández Fontecha, Elena ^a   Zubizarreta, Alberto ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Acute lymphoblastic leukemia; Acute myeloid leukemia; Asparaginase; Bone marrow transplantation; Cytatabin; Dexamethasone; Methotrexate; Pediatric; Prednisone

Indexed keywords

ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; ANTIMETABOLITE; ARSENIC TRIOXIDE; ASPARAGINASE; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; IDARUBICIN; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PODOPHYLLOTOXIN DERIVATIVE; PREDNISONE; RETINOIC ACID; TIOGUANINE; UNINDEXED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AVASCULAR NECROSIS; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CARDIOTOXICITY; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; FUTUROLOGY; HIGH RISK PATIENT; HUMAN; INFANT; REVIEW; TREATMENT OUTCOME; VEIN THROMBOSIS; WHOLE BODY RADIATION;

EID: 0035557999     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.1.3.479     Document Type: Review

References (87)

1. Acute lymphoblastic leukemia in children
2. Fifty years of studies of the biology and therapy of childhood leukemia
3. Acute lymphoblastic leukemia
4. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90
5. Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01
6. Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: Results from MRC UKALL XI and MRC ALL97 randomised trials
7. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: Results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991)
8. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995
9. Children's Cancer Group trials in childhood acute lymphoblastic leukemia, 1983-1995
10. Long-term results of three randomised trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: A CLCG-EORTC report
11. Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukemia, 1980-1997
12. Improving outcome through two decades in childhood ALL in the Nordic countries: The impact of high-dose methotrexate in the reduction of CNS irradiation
13. a for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital
14. Long-term follow-up of childhood acute lymphoblastic leukemia in Tokyo Children's Cancer Study Group 1981-1995
15. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86
16. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presentig features: A Childrens Cancer Group Phase III trial
17. Improved outcome in childhood acute lymphoblastic leukemia with reinforced early treatment and rotational combination chemotherapy
18. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia
19. Clearance of marrow infiltration after 1 week of therapy for childhood limphoblastic leukaemia: Clinical importance and the effect of daunorubicin
20. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood
21. A critical risk-benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia
22. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia
23. Differences in cerebrospinal fluid penetration of corticosteroids: Possible relationship to the prevention of meningeal leukemia
24. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia
25. Neuropsychologic effects of cranial irradiation, intrathecal methotrexate and systemic methotrexate in childhood cancer
26. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone
27. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia
28. The genetic origin of drug resistance in neoplasms: Implications for systemic therapy
29. Tumor size, sensitivity to therapy and design of treatment schedules
30. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group study
31. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy
32. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia
33. Allogeneic bone marrow transplantation in first remission for children with very high-risk acute lymphoblastic leukemia: A retrospective case-control study in the Nordic countries
34. Intensive chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia
35. Intensified therapy for infants with acute lymphoblastic leukemia: Results from the Dana-Farber Cancer Institute Consortium
36. High survival rate in infant acute leukemia treated with early high-dose chemotherapy and stem-cell support
37. New definition of remission in childhood acute lymphoblastic leukemia
38. Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: A Pediatric Oncology Group Study
39. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia
40. Long term survivors of childhood leukemia
41. Pharmacogenetics: Translating functional genomics into rational therapeutics
42. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia
43. Minimal residual disease after intensive therapy in childhood acute lymphoblastic leukemia predicts outcome
44. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia
45. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia
46. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia
47. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
48. The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: A report on the Medical Research Council UKALLR1 study
49. Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia
50. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome
51. Alternating drug pairs with or without periodic reinduction in children with acute lymphoblastic leukemia in second bone marrow remission: A Pediatric Oncology Group Study
52. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia
53. Idarubicin and cytosine arabinoside reinduction therapy for children with multiple recurrent or refractory acute lymphoblastic leukemia: A Pediatric Oncology Study Group study
54. Ifosfamide and etoposide in recurrent childhood acute lymphoblastic leukemia
55. Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down's syndrome and acute promyelocytic leukemia): Univariate and recursive partitioning analysis of patients Oncology Group (POG) Study 8821
56. The importance of diagnostic cytogenetics on outcome in AML analysis of 1612 patients entered into the MRC AML 10 trial
57. A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: Best outcome in girls, infants and children with Down's syndrome
58. Leukemia in Down's syndrome: A review
59. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: Results of the United Kingdom Medical Research Council's 10th AML trial
60. A randomised study of high-dose cytarabine in induction in acute myeloid leukemia
61. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the Children's Cancer Group
62. An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome
63. Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group
64. Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the Childhood Acute Myelogenous Leukemia Study BFM-87
65. Improvement in outcome for children receiving allogeneic bone marrow transplantation in first remission of acute myeloid leukemia: A report from the Groupe dÉtude des Greffes de Moelle Osseuse
66. Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: A report from the Childrens Cancer Group
67. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia
68. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood
69. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation and aggressive chemotherapy in children with acute myeloid leukemia in remission: A report from the Children's Cancer Group
70. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: Results of study Acute Myeloid Leukemia-Berlin-Frankurt-Münster 93
71. To the editor: Intensive chemotherapy versus bone marrow transplantation in pediatric acute myeloid leukemia: A matter of controversies
72. To the editor: Treatment of children with acute myeloid leukemia
73. Current issues in the management of acute promyelocytic leukemia
74. 2-Amino-9-β-D-arabinosyl-6-methoxy-9H-guanine (GW 506U; compound 506U) is highly active in patients with T-cell malignancies: Results of a Phase I trial in pediatric and adult patients with refractory hematological malignancies
75. An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia
76. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD-19-directed tyrosine kinase inhibitor
77. Unrelated donor bone marrow transplantation for children with acute leukemia
78. Unrelated donor marrow transplantation in children
79. Transplantation of anergic histoincompatible bone marrow allografts
80. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from a HLA-identical sibling
81. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
82. Antibody-targeted therapy for myeloid leukemia
83. FLAG (fludarabine, high-dose cytarabine and G-CSF) for refractory and high-risk relapsed acute leukemia in children
84. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients
85. A randomised Phase II study on the effects of 5-Aza-2′-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: An EORTC Leukemia Cooperative Group Phase II study (06893)
86. Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: A new approach to anti-leukemia therapy
87. Evidence of increased angiogenesis in patients with acute myeloid leukemia